Caplin Point Laboratories Limited

NSEI:CAPLIPOINT Voorraadrapport

Marktkapitalisatie: ₹149.4b

Caplin Point Laboratories Inkomsten in het verleden

Verleden criteriumcontroles 6/6

Caplin Point Laboratories has been growing earnings at an average annual rate of 18.9%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 16.9% per year. Caplin Point Laboratories's return on equity is 20.5%, and it has net margins of 27.2%.

Belangrijke informatie

18.9%

Groei van de winst

18.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie17.5%
Inkomstengroei16.9%
Rendement op eigen vermogen20.5%
Nettomarge27.2%
Volgende winstupdate07 Nov 2024

Recente prestatie-updates uit het verleden

Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

May 24
Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

Recent updates

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Oct 31
With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50

Sep 12
Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Aug 11
Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50

Aug 10
Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50

Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings

Jul 12
Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings

Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

May 24
Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?

May 04
Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement

Mar 07
Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Oct 24
With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise

Sep 15
Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50

Aug 11
Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50

We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

Sep 23
We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year

Sep 11
Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year

Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?

Jul 22
Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00

May 15
Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00

A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Jan 21
A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?

Oct 20
Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50

Sep 17
Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50

Sep 03
Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price

Aug 27
Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price

Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?

Jun 12
Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?

Estimating The Fair Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Apr 29
Estimating The Fair Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Does Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Have A Place In Your Dividend Portfolio?

Mar 24
Does Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Have A Place In Your Dividend Portfolio?

Opbrengsten en kosten

Hoe Caplin Point Laboratories geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NSEI:CAPLIPOINT Opbrengsten, kosten en inkomsten (INR Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2417,5774,7761,4870
31 Mar 2416,9614,5711,437737
31 Dec 2316,3184,3761,430632
30 Sep 2315,6834,1791,408632
30 Jun 2315,1573,9471,3960
31 Mar 2314,6833,7631,371632
31 Dec 2214,1823,5321,314593
30 Sep 2213,7243,3071,262593
30 Jun 2213,1533,1401,2100
31 Mar 2212,7102,9981,154593
31 Dec 2112,0992,8721,110537
30 Sep 2111,5812,7671,071537
30 Jun 2111,2172,5861,0340
31 Mar 2110,6242,4231,026537
31 Dec 209,9862,248952530
30 Sep 209,5242,189874530
30 Jun 209,1072,1937800
31 Mar 208,6402,150678530
31 Dec 198,3562,159617282
30 Sep 197,6642,032557282
30 Jun 196,9481,8945120
31 Mar 196,4901,766471282
31 Dec 186,0481,621449237
30 Sep 185,8741,538431237
30 Jun 185,6281,4594170
31 Mar 185,3991,448391237
31 Dec 175,1451,430367141
30 Sep 174,7571,297352141
30 Jun 174,4011,1653220
31 Mar 174,016956321141
31 Dec 163,65578330054
30 Sep 163,42070327454
30 Jun 163,23861925854
31 Mar 163,08858424054
31 Dec 152,90653529867
30 Sep 152,72246528360
30 Jun 152,51841020359
31 Mar 152,29635323353
31 Dec 142,07431822042
30 Sep 141,89330520433
30 Jun 141,73125819021
31 Mar 141,6432041664
31 Dec 131,5171671490

Kwaliteitswinsten: CAPLIPOINT has high quality earnings.

Groeiende winstmarge: CAPLIPOINT's current net profit margins (27.2%) are higher than last year (26%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: CAPLIPOINT's earnings have grown by 18.9% per year over the past 5 years.

Versnelling van de groei: CAPLIPOINT's earnings growth over the past year (21%) exceeds its 5-year average (18.9% per year).

Winst versus industrie: CAPLIPOINT earnings growth over the past year (21%) exceeded the Pharmaceuticals industry 19.1%.


Rendement op eigen vermogen

Hoge ROE: CAPLIPOINT's Return on Equity (20.5%) is considered high.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden